Wexford Capital’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Wexford Capital’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-500,000	Closed	-$280K	–	175
2019 Q3	$280K	Hold	500,000	–	–	0.04%	99
2019 Q2	$260K	Hold	500,000	–	–	0.03%	111
2019 Q1	$225K	Hold	500,000	–	–	0.02%	88
2018 Q4	$240K	Hold	500,000	–	–	0.02%	73
2018 Q3	$265K	Hold	500,000	–	–	0.02%	131
2018 Q2	$250K	Hold	500,000	–	–	0.02%	109
2018 Q1	$211K	Hold	500,000	–	–	0.02%	104
2017 Q4	$190K	Buy	+500,000	New	+$190K	0.02%	117

Other funds holding GCVRZ

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

MCM

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

BCM

Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

NGA

New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

MFP

Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Wexford Capital's GCVRZ Position: Q4 2019 in Review

Wexford Capital sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2019, closing a stake of 500,000 shares — an estimated $280K sold.

Wexford Capital first reported a position in GCVRZ in Q4 2017 and held it in 8 quarters. The position peaked at $280K in Q3 2019. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2019.

Wexford Capital reported no remaining Sanofi Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
Wexford Capital sold 500,000 Sanofi Contingent Value Rights shares in Q4 2019, an estimated $280K.
Wexford Capital first reported a position in Sanofi Contingent Value Rights in Q4 2017 and held it in 8 quarters.
Wexford Capital's Sanofi Contingent Value Rights position peaked at $280K in Q3 2019.
103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2019.

Based on Wexford Capital's 13F filing for Q4 2019, filed 14 Feb 2020.